<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024790" disease_type="Disease or Syndrome" abbrv="PNH">Paroxysmal nocturnal haemoglobinuria</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are disorders of pluripotent stem cells resulting in haematopoietic insufficiency which can be cured by marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The extent of myeloablative conditioning necessary for elimination of the non-malignant and premalignant clones is not known </plain></SENT>
<SENT sid="2" pm="."><plain>We report our results of marrow transplantation with and without myeloablative conditioning in two patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and seven patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Conditioning was not used in a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and a monozygotic twin as donor </plain></SENT>
<SENT sid="4" pm="."><plain>In this patient the disease remained unchanged </plain></SENT>
<SENT sid="5" pm="."><plain>Myeloablative treatment with busulphan (BUS) in addition to immunosuppression with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) was used for conditioning in a patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and a 2-year-old boy with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="6" pm="."><plain>Fractionated total body irradiation (FTBI) and CY was used in six patients with refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in leukaemic transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>Haematopoiesis was fully restored in <z:hpo ids='HP_0000001'>all</z:hpo> patients conditioned with myeloablative treatment except for a patient in leukaemic transformation with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and a HLA-DR-incompatible donor </plain></SENT>
<SENT sid="8" pm="."><plain>Chimerism was complete in <z:hpo ids='HP_0000001'>all</z:hpo> patients except for the 2-year-old boy conditioned with BUS and CY </plain></SENT>
<SENT sid="9" pm="."><plain>Our results and those reviewed in the literature indicate that myeloablative conditioning with either BUS or FTBI is advantageous for marrow transplantation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>